Immunocore (IMCR) to Release Quarterly Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is projected to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Immunocore to post earnings of ($0.28) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 2:00 AM ET.

Immunocore Price Performance

Shares of IMCR opened at $32.38 on Wednesday. Immunocore has a twelve month low of $23.15 and a twelve month high of $40.71. The firm has a 50 day moving average of $34.02 and a 200 day moving average of $34.32. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $1.64 billion, a P/E ratio of -56.81 and a beta of 0.78.

Institutional Investors Weigh In On Immunocore

A number of hedge funds and other institutional investors have recently bought and sold shares of IMCR. Arax Advisory Partners increased its holdings in shares of Immunocore by 302.9% during the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after acquiring an additional 1,042 shares in the last quarter. Osaic Holdings Inc. increased its stake in Immunocore by 117.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after purchasing an additional 1,700 shares in the last quarter. State of Tennessee Department of Treasury acquired a new position in Immunocore during the 2nd quarter valued at approximately $132,000. Federation des caisses Desjardins du Quebec raised its holdings in shares of Immunocore by 162.1% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock worth $190,000 after buying an additional 3,388 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of Immunocore during the fourth quarter worth $203,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on IMCR shares. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, February 4th. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Wells Fargo & Company initiated coverage on Immunocore in a research note on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective for the company. Morgan Stanley boosted their price objective on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Finally, Zacks Research raised Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and an average price target of $60.40.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.